Novel findings in relation to multiple anti‐atherosclerotic effects of XueZhiKang in humans

Chronic Diseases and Translational Medicine - Tập 4 - Trang 117-126 - 2018
Rui-Xia Xu1, Yan Zhang1, Yuan-Lin Guo1, Chun-Yan Ma1, Yu-Hong Yao1, Sha Li1, Xiao-Lin Li1, Ping Qing1, Ying Gao1, Na-Qiong Wu1, Cheng-Gang Zhu1, Geng Liu1, Qian Dong1, Jing Sun1, Jian-Jun Li1
1Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China

Tóm tắt

AbstractBackgroundPrevious studies have clearly demonstrated that XueZhiKang (XZK), an extract of cholestin, can decrease low‐density lipoprotein cholesterol (LDL‐C) and cardiovascular events. However, the mechanism of the effects of XZK on atherosclerosis (AS) in humans has been reported less frequently. In the present study, we investigated the impact of XZK on lipoprotein subfractions, oxidized LDL (oxLDL), and interleukin‐6 (IL‐6).MethodsFrom October 2015 to July 2016, 40 subjects were enrolled in this study. Of them, 20 subjects with dyslipidemia received XZK 1200 mg/day for 8 weeks (XZK group); 20 additional healthy subjects who did not receive therapy acted as controls. The plasma lipoprotein subfractions, oxLDL, and IL‐6 were examined at baseline and again at 8 weeks.ResultsData showed that XZK could significantly decrease not only plasma LDL‐C levels (87.26 ± 24.45 vs. 123.34 ± 23.99, P < 0.001), total cholesterol (4.14 ± 0.87 vs. 5.08 ± 1.03, P < 0.001), triglycerides (0.95 ± 0.38 vs. 1.55 ± 0.61, P < 0.05), and apolipoprotein B (1.70 ± 0.35 vs. 1.81 ± 0.72, P < 0.05), but also oxLDL (36.36 ± 5.31 vs. 49.20 ± 15.01, P < 0.05) and IL‐6 (8.50 ± 7.40 vs. 10.40 ± 9.49, P < 0.05). At the same time, XZK reduced the concentration of small LDL‐C (1.78 ± 2.17 vs. 6.33 ± 7.78, P < 0.05) and the percentage of the small LDL subfraction (1.09 ± 1.12 vs. 3.07 ± 3.09, P < 0.05).ConclusionsTreatment with 1200 mg/day XZK for 8 weeks significantly decreased the atherogenic small LDL subfraction and reduced oxidative stress and inflammatory markers, in addition to affecting the lipid profile, suggesting multiple beneficial effects in coronary artery disease.

Tài liệu tham khảo

10.1161/CIRCRESAHA.111.261388 10.1016/j.jacc.2013.07.051 10.1186/1471-2458-14-545 Li J.J., 2011, Inflammation in coronary artery diseases, Chin Med J Engl, 124, 3568 10.1097/MCA.0b013e3282fd5c4e 10.1016/j.arr.2007.09.001 10.1159/000447558 10.1093/ehjci/jew173 10.1159/000453202 10.1161/STROKEAHA.116.014816 Zhang L., 2016, Trichosanatine alleviates oxidized low‐density lipoprotein induced endothelial cells injury via inhibiting the LOX‐1/p38 MAPK pathway, Am J Transl Res, 8, 5455 10.1016/j.cca.2012.09.010 10.1016/j.jacl.2012.03.001 10.1373/clinchem.2010.155333 10.1177/0091270009337509 10.1007/s11655-014-1846-y 10.1111/j.1532-5415.2007.01230.x 10.1177/0091270009337509 10.1111/j.1365-2362.2011.02629.x 10.1038/jhh.2011.108 10.1111/1440-1681.12243 Wang Y., 2014, Adjunctive therapy of xuezhikang capsule for coronary heart disease: a systematic review and meta‐analysis of randomized controlled trials [in Chinese], Zhongguo Zhong Xi Yi Jie He Za Zhi, 34, 1182 10.1016/j.jacl.2014.09.002 10.1016/j.amjcard.2008.02.056 10.1016/j.cccn.2004.09.026 10.1155/2014/781780 Chen Y., 2014, Efficacy and safety comparison of different statins in elderly patients [in Chinese], Zhonghua Xin Xue Guan Bing Za Zhi, 42, 910 Ni L., 2013, Multi‐centered, randomized controlled clinical study on Chinese medicine formula particles for hyperlipidaemia associated with highly active antiretroviral therapy [in Chinese], Zhongguo Zhong Yao Za Zhi, 38, 2443 Li Y., 2014, A meta‐analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia, PLoS One, 9 10.1038/nrd4279 10.1161/CIRCULATIONAHA.105.565135 10.1016/j.beem.2013.11.001 10.1016/j.hlc.2015.05.002 10.1161/circ.106.25.3143 10.1210/jc.2010-2170 10.1016/j.cca.2007.10.033 Williams P.T., 2013, Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL‐Atherosclerosis Treatment Study (HATS), PLoS One, 8 10.1186/1476-511X-13-188 10.1016/j.numecd.2015.01.006 10.1016/j.atherosclerosis.2014.03.002 10.1155/2008/371314 10.1016/j.ijcard.2005.11.006 10.1016/j.jnutbio.2016.05.002 Jiang F.Y., 2011, Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention [in Chinese], Zhongguo Zhong Xi Yi Jie He Za Zhi, 31, 1607 Huang J., 2006, Effects of Xuezhikang on serum levels of high sensitive‐C reactive protein, matrix metalloproteinase‐9 and lipoprotein in patients with acute coronary syndrome [in Chinese], Zhongguo Zhong Xi Yi Jie He Za Zhi, 26, 221 10.1016/j.ijcard.2006.11.031 10.1016/j.cca.2015.04.032
Thông tin
Thông tin xuất bản

Chronic Diseases and Translational Medicine

Tập 4

117-126

Thông tin tác giả